Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
03 Maio 2024 - 8:30AM
Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a
biopharmaceutical company committed to enhancing people’s vision
and quality of life through the development and commercialization
of innovative therapies for wet age-related macular degeneration
(wet AMD), diabetic retinopathy, and other diseases and conditions
of the eye, announced multiple presentations at the Ophthalmology
Innovation Source (OIS) Retina 2024 (May 4th) and the Association
for Research in Vision and Ophthalmology (ARVO) 2024 meetings (May
5-9th) being held in Seattle, Washington.
Presentations at OIS Retina 2024:
- Session Title: “Spotlight on Drug Delivery”Session Date/Time:
Saturday, May 4th, 11:15 AM – 12:00 PM PDTOcular Presentation:
11:34 – 11:41 AM PDTPresenter: Sanjay Nayak, MBBS, PhD, Chief
Strategy Officer
- Panel Title: “The View from the
Street”Session Date/Time: Saturday, May 4th at 5:00 – 5:30 PM
PDTModerator: Pravin U. Dugel, MD, Executive Chairman, President
and Chief Executive Officer
Presentations at ARVO 2024:
- Oral Presentation: Pharmacodynamic efficacy of
second-generation intravitreal axitinib implant (AXPAXLI) in a VEGF
challenge rabbit modelSession Date/Time: Thursday, May 9th
3:30 – 3:45 PM PDTLocation: Yakima 1 - Seattle Convention Center -
Arch BuildingPresenter: Chuck Blizzard, Vice President, Research
& Development
- Poster Title: Long-term safety
of repeated intravitreal axitinib implant (AXPAXLI) administrations
in non-human primatesPoster Board #: B0299Session
Date/Time: Monday, May 6th 8:30 – 10:15 AM PDTLocation: Exhibit
Hall – Seattle Convention CenterPresenter: Chintan Patel, PhD,
Associate Director, Nonclinical Development
- Poster Title: Optimized
pharmacokinetic profile of intravitreal axitinib implant
(AXPAXLI): a comparison of first- and
second-generation implantsPoster Board #: B0300Session
Date/Time: Monday, May 6th 8:30 – 10:15 AM PDTLocation: Exhibit
Hall – Seattle Convention CenterPresenter: Madhoosudan Patil, PhD,
Senior Scientist
About Ocular
Therapeutix, Inc.Ocular
Therapeutix, Inc. is a biopharmaceutical company committed to
enhancing people’s vision and quality of life through the
development and commercialization of innovative therapies for wet
age-related macular degeneration (wet AMD), diabetic retinopathy
(DR), and other diseases and conditions of the
eye. AXPAXLI™ (axitinib intravitreal implant, also known
as OTX-TKI), Ocular’s product candidate for retinal disease, is
based on its ELUTYX™ proprietary bioresorbable hydrogel-based
formulation technology. AXPAXLI is currently in the first of two
planned pivotal Phase 3 trials for wet AMD,
the SOL-1 trial, and a Phase 1 clinical trial for the
treatment of NPDR. The clinical portfolio also
includes PAXTRAVA™ (travoprost intracameral implant, also
known as OTX-TIC), currently in a Phase 2 clinical trial for the
treatment of primary open-angle glaucoma or ocular
hypertension.
Ocular’s expertise in the formulation, development and
commercialization of innovative therapies of the eye and the ELUTYX
platform supported the development and launch of its first
commercial drug product, DEXTENZA®, an FDA-approved
corticosteroid for the treatment of ocular inflammation and pain
following ophthalmic surgery and ocular itching associated with
allergic conjunctivitis. ELUTYX is also the foundation for two
other clinical-stage assets, OTX-CSI (cyclosporine
intracanalicular insert) for the chronic treatment of dry eye
disease and OTX-DED (dexamethasone intracanalicular
insert) for the short-term treatment of the signs and symptoms of
dry eye disease, as well as several preclinical programs.
Follow us on our website, LinkedIn or X.
DEXTENZA® is a registered trademark of Ocular
Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, and ELUTYX™ and Ocular
Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
About DEXTENZA
DEXTENZA is FDA-approved for the treatment of ocular
inflammation and pain following ophthalmic surgery and ocular
itching associated with allergic conjunctivitis. DEXTENZA is a
corticosteroid intracanalicular insert placed in the punctum, a
natural opening in the inner portion of the lower eyelid, and into
the canaliculus, and is designed to deliver dexamethasone to the
ocular surface for up to 30 days without preservatives. DEXTENZA
resorbs and exits the nasolacrimal system without the need for
removal.
Please see full Prescribing and Safety Information at
the DEXTENZA website.
Forward-Looking StatementsAny statements in
this press release about future expectations, plans, and prospects
for the Company, including the development and regulatory status of
the Company’s product candidates, including the timing, design, and
enrollment of the Company’s Phase 3 trials of AXPAXLI (also called
OTX-TKI) for the treatment of wet AMD and the Company’s planned
Phase 3 clinical development program of AXPAXLI for the treatment
of diabetic retinopathy; the Company’s plans to advance the
development of AXPAXLI, PAXTRAVA and its other product candidates;
the potential utility of any of the Company’s product candidates;
the sufficiency of the Company’s cash resources; and other
statements containing the words “anticipate”, “believe”,
“estimate”, “expect”, “intend”, “goal”, “may”, “might”, “plan”,
“predict”, “project”, “target”, “potential”, “will”, “would”,
“could”, “should”, “continue”, and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors. Such forward-looking
statements involve substantial risks and uncertainties that could
cause the Company’s preclinical and clinical development programs,
future results, performance or achievements to differ significantly
from those expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, the timing and
costs involved in commercializing DEXTENZA or any product or
product candidate that receives regulatory approval; the ability to
retain regulatory approval of DEXTENZA or any product or product
candidate that receives regulatory approval; the initiation,
design, timing, conduct and outcomes of clinical trials, including
the SOL-1 trial, the HELIOS trial, and the planned Phase 3 clinical
development program of AXPAXLI for diabetic retinopathy as well as
the Company’s other ongoing clinical trials; the risk that the FDA
will not agree with the Company’s interpretation of the written
agreement under Special Protocol Assessment for the SOL-1 trial;
the risk that even though the FDA has agreed with the overall
design of the SOL-1 trial, the FDA may not agree that the data
generated by the SOL-1 trial supports potential marketing approval;
uncertainty as to whether the data from earlier clinical trials
will be predictive of the data of later clinical trials,
particularly later clinical trials that have a different design or
utilize a different formulation than the earlier trials, or whether
preliminary or interim data from a clinical trial will be
predictive of final data from such trial; availability of data from
clinical trials and expectations for regulatory submissions and
approvals; the Company’s scientific approach and general
development progress; uncertainties inherent in estimating the
Company’s cash runway, future expenses and other financial results,
including its ability to fund future operations, including clinical
trials; the Company’s existing indebtedness and the ability of the
Company’s creditors to accelerate the maturity of such indebtedness
upon the occurrence of certain events of default; the Company’s
ability to enter into strategic alliances or generate additional
funding on a timely basis, on favorable terms, or at all; and other
factors discussed in the “Risk Factors” section contained in the
Company’s quarterly and annual reports on file with the Securities
and Exchange Commission. In addition, the forward-looking
statements included in this press release represent the Company’s
views as of the date of this press release. The Company anticipates
that subsequent events and developments will cause the Company’s
views to change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so, whether as
a result of new information, future events or otherwise, except as
required by law. These forward-looking statements should not be
relied upon as representing the Company’s views as of any date
subsequent to the date of this press release.
Investors & MediaOcular Therapeutix,
Inc.Bill SlatteryVice President, Investor
Relationsbslattery@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ocular Therapeutix (NASDAQ:OCUL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024